Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1054/jocn.2000.0790 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful pregnancy outcome in a recipient of simultaneous pancreatic kidney transplantation.
BMJ Case Rep
January 2025
Obstetrics and Gynecology, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India.
There is limited information available regarding post-simultaneous pancreatic kidney transplantation (SPKT) pregnancies. The present case describes a woman in her early 30s with first pregnancy who conceived spontaneously 4 years after SPKT. Her pancreatic and kidney graft function remained stable throughout the pregnancy.
View Article and Find Full Text PDFBoosting CAR-T cell therapy through vaccine synergy.
Trends Pharmacol Sci
January 2025
Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Parker Institute for Cancer Immunotherapy, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address:
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematological cancers. However, achieving comparable success in solid tumors remains challenging. Factors contributing to these limitations include the scarcity of tumor-specific antigens (TSAs), insufficient CAR-T cell infiltration, and the immunosuppressive tumor microenvironment (TME).
View Article and Find Full Text PDFHydrogel injection molded complex macroencapsulation device geometry improves long-term cell therapy viability and function in the rat omentum transplant site.
Biomaterials
December 2024
School of Biological and Health Systems Engineering, Arizona State University, 550 East Orange St., Tempe, AZ, 85281, USA. Electronic address:
Insulin-secreting allogeneic cell therapies are a promising treatment for type 1 diabetes, with the potential to eliminate hypoglycemia and long-term complications of the disease. However, chronic systemic immunosuppression is necessary to prevent graft rejection, and the acute risks associated with immunosuppression limit the number of patients who can be treated with allogeneic cell therapies. Islet macroencapsulation in a hydrogel biomaterial is one proposed method to reduce or eliminate immune suppression; however, macroencapsulation devices suffer from poor oxygen transport and limited efficacy as they scale to large animal model preclinical studies and clinical trials.
View Article and Find Full Text PDFEfficacy and Safety of Intravenous Immunoglobulin (IVIg) in Acute Viral Myocarditis in Children: A Systematic Review of Randomized Controlled Trials.
Indian Pediatr
January 2025
Indian Council of Medical Research (ICMR) Advanced Centre for Evidence Based Child Health (ACEBCH) and Department of Pediatrics, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Context: Acute myocarditis is a rare but potentially life-threatening condition in infants and children. While immunosuppressive agents have shown limited effectiveness, intravenous immunoglobulin (IVIg) holds promise as a treatment option.
Objective: To study the efficacy and safety of intravenous immunoglobulin (IVIg) in treating acute viral myocarditis in children.
Emerging Novel Combined CAR-NK Cell Therapies in Cancer Treatment: Finding a Dancing Partner.
Mol Ther
January 2025
Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of California, Irvine, CA; Chao Family Comprehensive Cancer Center, University of California, Irvine, CA. Electronic address:
In recent decades, immunotherapy with chimeric antigen receptors (CAR) has revolutionized cancer treatment and given hope where other cancer therapies have failed. CAR-NK cells are NK cells that have been engineered ex vivo with a CAR on the cell membrane with high specificity for specific target antigens of tumor cells. The impressive results of several studies suggest that CAR-NK cell therapy has significant potential and successful performance in cancer treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!